

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

Vero/TMPRSS2

RRID:CVCL_YQ48

Type: Cell Line

Proper Citation

JCRB Cat# JCRB1818, RRID:CVCL_YQ48

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_YQ48

Proper Citation: JCRB Cat# JCRB1818, RRID:CVCL_YQ48

Description: Cell line Vero/TMPRSS2 is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus (Green monkey)

Sex: Female

Defining Citation: [PMID:18562527](#)

Comments: Group: SARS-CoV-2 research cell line., Group: Non-human primate cell line.

Category: Spontaneously immortalized cell line

Organism: Chlorocebus sabaeus (Green monkey)

Name: Vero/TMPRSS2

Cross References: JCRB:JCRB1818, Wikidata:Q98134516

ID: CVCL_YQ48

Vendor: JCRB

Catalog Number: JCRB1818

Hierarchy: cvcl_0059

Record Creation Time: 20250130T073020+0000

Record Last Update: 20260905T184220+0000

Ratings and Alerts

No rating or validation information has been found for Vero/TMPRSS2.

No alerts have been found for Vero/TMPRSS2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 157 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sasaki Y, et al. (2024) Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy: For suppression of lymph node and distant metastasis in a murine melanoma model. Biochemical and biophysical research communications, 740, 151011.

Mommert-Tripon M, et al. (2024) Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection. EBioMedicine, 110, 105450.

Zhang F, et al. (2023) Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies. Nature microbiology, 8(6), 1051.

Sasaki M, et al. (2023) S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Science translational medicine, 15(679), eabq4064.

Deng S, et al. (2023) An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Nature communications, 14(1), 2081.

Kawakami E, et al. (2023) Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19. Cell stem cell, 30(10), 1315.

Komori M, et al. (2023) saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern. Nature communications, 14(1), 2810.

Dickey TH, et al. (2023) Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines. Cell reports, 42(3), 112266.

Qu Y, et al. (2023) SARS-CoV-2 Inhibits NRF2-Mediated Antioxidant Responses in Airway Epithelial Cells and in the Lung of a Murine Model of Infection. Microbiology spectrum, e0037823.

Hastie KM, et al. (2023) Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6??months before Omicron emergence. Cell reports, 42(5), 112421.

Carlin AF, et al. (2023) 1-O-Octadecyl-2-O-benzyl-sn-glycerol-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity. *Journal of medicinal chemistry*, 66(8), 5802.

Kwon T, et al. (2023) Ancestral Lineage of SARS-CoV-2 Is More Stable in Human Biological Fluids than Alpha, Beta, and Omicron Variants of Concern. *Microbiology spectrum*, 11(1), e0330122.

Braun MR, et al. (2023) Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. *Frontiers in immunology*, 14, 1086035.

Panzer Y, et al. (2023) Detection and genome characterisation of SARS-CoV-2 P.6 lineage in dogs and cats living with Uruguayan COVID-19 patients. *Memorias do Instituto Oswaldo Cruz*, 117, e220177.

Jochmans D, et al. (2023) The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CL^{pro} Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. *mBio*, 14(1), e0281522.

Ying B, et al. (2023) A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters. *bioRxiv : the preprint server for biology*.

Desautels TA, et al. (2023) Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants. *bioRxiv : the preprint server for biology*.

Patel A, et al. (2023) Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response. *Structure (London, England : 1993)*, 31(7), 801.

Wing PAC, et al. (2023) An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity. *PLoS pathogens*, 19(5), e1011323.

McConnell SA, et al. (2023) Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization. *Cell chemical biology*, 30(7), 726.